deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01967888

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Sponsor: Dompé Farmaceutici S.p.A

Conditions Pancreatectomy for Chronic Pancreatitis
Interventions Placebo Reparixin
Updated 14 times since 2017 Last updated: Oct 30, 2023 Started: Feb 28, 2014 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01967888, this PHASE2/PHASE3 trial focuses on Pancreatectomy for Chronic Pancreatitis and remains completed. Sponsored by Dompé Farmaceutici S.p.A, it has been updated 14 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2018 · 15 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2019 · 16 months · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Aug 2023 · 20 months · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Aug 2023 — Dec 2023 [monthly]

    Completed PHASE2_PHASE3

  5. Dec 2021 — Aug 2023 [monthly]

    Completed PHASE2_PHASE3

▶ Show 9 earlier versions

  1. Nov 2021 — Dec 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Jan 2021 — Nov 2021 [monthly]

    Completed PHASE2_PHASE3

  3. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  4. Nov 2019 — Aug 2020 [monthly]

    Completed PHASE2_PHASE3

  5. Jul 2018 — Nov 2019 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  7. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  8. Feb 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dompé Farmaceutici S.p.A
Data source: Dompé Farmaceutici S.p.A

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations